| 16.5 2.2 (15.38%) | 11-04 14:08 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 20.44 |
1-year : | 23.87 |
| Resists | First : | 17.5 |
Second : | 20.44 |
| Pivot price | 14.48 |
|||
| Supports | First : | 13.94 |
Second : | 11.75 |
| MAs | MA(5) : | 15.75  |
MA(20) : | 14.09 |
| MA(100) : | 14.21 |
MA(250) : | 16.76 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 68.4 |
D(3) : | 63.2 |
| RSI | RSI(14): 57.3 |
|||
| 52-week | High : | 22.14 | Low : | 9.97 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ZIVO ] has closed below upper band by 16.6%. Bollinger Bands are 12.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.51 - 16.63 | 16.63 - 16.72 |
| Low: | 16.28 - 16.4 | 16.4 - 16.5 |
| Close: | 16.34 - 16.53 | 16.53 - 16.68 |
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.
Mon, 03 Nov 2025
Is ZIVO Bioscience Inc. (9R80) stock ideal for retirement investors - July 2025 Recap & High Conviction Buy Zone Picks - newser.com
Mon, 03 Nov 2025
Can ZIVO Bioscience Inc. (9R80) stock withstand sector downturns - 2025 Top Gainers & AI Enhanced Trading Alerts - newser.com
Mon, 03 Nov 2025
Why ZIVO Bioscience Inc. (9R80) stock stays undervalued - Dip Buying & Verified Swing Trading Watchlist - newser.com
Mon, 03 Nov 2025
Is ZIVO Bioscience Inc. (9R80) stock overpriced at current multiples - 2025 Support & Resistance & Long-Term Safe Return Strategies - newser.com
Sun, 02 Nov 2025
Can ZIVO Bioscience Inc. (9R80) stock withstand sector downturns - 2025 Trade Ideas & Real-Time Volume Analysis Alerts - newser.com
Sun, 02 Nov 2025
Can ZIVO Bioscience Inc. (9R80) stock withstand sector downturns - Weekly Earnings Recap & Low Drawdown Investment Strategies - newser.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 3.37e+006 (%) |
| Held by Institutions | 1.77e+006 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -5.33 |
| Profit Margin | 0 % |
| Operating Margin | -21 % |
| Return on Assets (ttm) | 871.9 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -3.1 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 35470 |
| Forward Dividend | 12810 |
| Dividend Yield | 214970% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|